Expert Review of Clinical Immunology

Papers
(The median citation count of Expert Review of Clinical Immunology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus109
Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients84
An updated review on Mendelian susceptibility to mycobacterial diseases– a silver jubilee celebration of its first genetic diagnosis82
A review of disease burden and clinical management for generalized pustular psoriasis in China78
Managing acute COVID-19 in immunocompromised pediatric patients76
Genetic syndromes and autoimmunity: what do we know? Focus on Down and Turner syndrome61
Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients58
Pharmacogenetics of childhood uncontrolled asthma58
A review of current biomarkers in chronic rhinosinusitis with or without nasal polyps56
The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease48
Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens44
Vitamin D as disease-modifying therapy for multiple sclerosis?32
Clinical updates in neoadjuvant immunotherapy for melanoma before surgery32
Predicting lupus low disease activity state and remission in SLE: novel insights30
Epinephrine treatment of food-induced and other cause anaphylaxis in United States and Canadian Emergency Departments: a systematic review and meta-analysis30
Lymphocyte-C-reactive protein ratio combined with albumin upon admission predicts coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease: a retrospective cohort st29
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience28
Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook26
Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease25
Precision medicine in the allergy clinic: the application of component resolved diagnosis25
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy24
Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo24
Anoikis and SPP1 in idiopathic pulmonary fibrosis: integrating bioinformatics, cell, and animal studies to explore prognostic biomarkers and PI3K/AKT signaling regulation24
A critical review of dupilumab for adult patients with prurigo nodularis24
How could our genetics impact COVID-19 vaccine response?23
Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward22
An immunologist’s guide to immunosenescence and its treatment21
Cellular mechanisms and clinical applications for phenocopies of inborn errors of immunity: infectious susceptibility due to cytokine autoantibodies21
Targeting the microbiome in Crohn’s disease20
Examining the autoimmune aspects of frontal fibrosing alopecia20
Bradford Hill and breast implant illness: no evidence for causal association with breast implants20
The Impact of Preeclampsia in Lupus Nephritis20
What is the full potential of baricitinib in treating patients with COVID-19?19
BRAF inhibitors and their immunological effects in malignant melanoma19
Assessing the potential of epigenetic targets as biomarkers in the diagnosis and treatment of rheumatoid arthritis18
The multidisciplinary approach to diagnosing inborn errors of immunity: a comprehensive review of discipline-based manifestations18
A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort16
Telemedicine beyond the pandemic: challenges in the pediatric immunology clinic16
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection16
Tofacitinib for the treatment of active ankylosing spondylitis in adults15
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis15
Immunobiology and treatment of cutaneous T-cell lymphoma15
Will SARS-CoV-2 impact the incidence and nature of other respiratory infections?15
Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis15
Eosinophilic esophagitis: does age matter?14
Bimekizumab for the treatment of psoriatic arthritis14
Olfactory dysfunction in chronic rhinosinusitis: insights into the underlying mechanisms and treatments13
Why do drug treatments fail in Sjögren’s disease? Considerations for treatment, trial design and interpretation of clinical efficacy13
Molecular genotyping versus serological diagnosis for RH blood group typing in sickle cell patients13
Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype13
Immune dysfunction in inborn errors of immunity causing malignancies13
A critical evaluation of nemolizumab for prurigo nodularis13
Peanut (Arachis hypogaea) allergen powder-dnfp for the mitigation of allergic reactions to peanuts in children and adolescents12
Proportion of T follicular helper cells in peripheral blood of rheumatoid arthritis patients: a systematic review and meta-analysis12
Biological drugs for the treatment of children with chronic spontaneous urticaria12
Innovative treatments for severe uncontrolled chronic rhinosinusitis with nasal polyps12
Machine learning method for the cellular phenotyping of nasal polyps from multicentre tissue scans12
The methylenetetrahydrofolate reductase 1298 A>C polymorphism is associated with an increased risk of inflammatory bowel disease: evidence from a meta-analysis12
Efficacy and safety of subcutaneous immunotherapy with polymerized allergen mixtures in polyallergic patients – ARES observational study12
Pan-cancer analysis of the prognostic significance of ACKR2 expression and the related genetic/epigenetic dysregulations11
The role of fibroblast in chronic rhinosinusitis with nasal polyps: a key player in the inflammatory process11
Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors11
A prospective single-arm study on the efficacy and safety of short-course oral corticosteroids followed by topical corticosteroids in patients with severe chronic rhinosinusitis with nasal polyps11
New therapeutic concepts against ischemia-reperfusion injury in organ transplantation11
The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation11
Prognostic factors for post-operative outcomes in chronic rhinosinusitis with nasal polyps: a systematic review11
Pioglitazone as a potential modulator in autoimmune diseases: a review on its effects in systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and multiple sclerosis11
Update on virus-induced asthma exacerbations10
The role of IL-6 and IL-6 blockade in COVID-1910
Growth differentiation factor-15 as an emerging biomarker for identifying myositis10
Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions10
Model-based computational precision medicine to develop combination therapies for autoimmune diseases10
Generalized pustular psoriasis: current management status and unmet medical needs in Japan10
Personalizing therapy selection in inflammatory bowel disease10
IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma10
Challenges and management of childhood noninfectious chronic uveitis10
An update on VEXAS syndrome10
Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine10
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus10
Re-evaluation of nailfold capillaroscopy in discriminating primary from secondary Raynaud’s phenomenon and in predicting systemic sclerosis: a randomised observational prospective cohort study9
Comparison of high- and low-molecular-weight sensitizing agents causing occupational asthma: an evidence-based insight9
The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren’s syndrome related dry eye9
How suitable is intravenous tocilizumab for the treatment of Graves’ ophthalmopathy?9
More than a random association between chronic obstructive pulmonary disease and psoriatic arthritis: shared pathogenic features and implications for treatment9
Could small molecules be used in combination with biologics for inflammatory bowel disease?9
How best to manage relapse and remission in ANCA-associated vasculitis9
Machine learning and artificial intelligence within pediatric autoimmune diseases: applications, challenges, future perspective9
Pathophysiology of rejection in kidney transplantation9
What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?9
An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and meta-analysis9
Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients9
An evaluation of anifrolumab for use in adults with systemic lupus erythematosus9
Risk of infections in psoriasis: assessment and challenges in daily management9
Filgotinib in rheumatoid arthritis9
Mast cell activation: beyond histamine and tryptase8
Novel insights into central compartment atopic disease - a literature review8
Tapinarof cream for the topical treatment of plaque psoriasis in adults8
What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?8
Clinical guide to eosinophilic fasciitis: straddling dermatology and rheumatology8
Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies8
Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review8
The (apparent) antibody paradox in COVID-198
Corticosteroid-eluting implants for the management of chronic rhinosinusitis with or without nasal polyps8
Managing psoriatic arthritis in different clinical scenarios8
Rationale for IL-37 as a novel therapeutic agent in inflammation8
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications8
Genetic variations in the human immune system influence susceptibility to tegumentary leishmaniasis: a systematic review and meta-analysis8
Systemic therapy in juvenile localized scleroderma8
Role of tight junction proteins in shaping the immune milieu of malignancies8
Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician8
Food immunotherapy: current status and future needs8
Role of CD68 in the tumor immune microenvironment in Hodgkin’s lymphoma8
Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives8
Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge8
Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy8
Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort8
Recent insights into the impacts of COVID-19 on pediatric asthma8
Could we co-opt the cannabinoid system for asthma therapy?8
Pediatric chronic spontaneous urticaria: a brief clinician’s guide8
The relationship between bullous pemphigoid and renal disease and related treatments: a review of the current literature7
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial7
Autoimmune hemolytic anemia: causes and consequences7
Epstein–Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge7
The clinical role of anakinra in the armamentarium against familial Mediterranean fever7
Matrix metalloproteinases in chronic rhinosinusitis7
Upadacitinib for the treatment of adult patients with active psoriatic arthritis7
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate7
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives7
Tackling medical misinformation in allergy and immunology practice7
Isolation and analysis of the exosomal membrane proteins in bullous pemphigoid7
How to and should we target EBV in MS?7
Oral immunotherapy for food allergy in children: is it worth it?7
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm7
Correction7
LncRNA ZFAS1/miR-186-5p axis is involved in oxidative stress inhibition of myocardial ischemia-reperfusion injury by targeting BTG26
The role of genetics in food allergy6
Current evaluation and management of patients with chronic rhinosinusitis and nasal polyps6
CAR-T cell technologies that interact with the tumour microenvironment in solid tumours6
Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis6
Differential risk of autoimmune disorders in non-traumatic osteonecrosis: clue to pathogenesis6
Early diagnosis of systemic sclerosis, where do we stand today?6
Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies – real-world data from the IG TATRY study6
Rare forms of inflammatory myopathies – part I, generalized forms6
Endosomal Toll-Like Receptors intermediate negative impacts of viral diseases, autoimmune diseases, and inflammatory immune responses on the cardiovascular system6
How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?6
Novel therapeutic approaches for cutaneous T cell lymphomas6
Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease6
Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis6
Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM6
Biological therapy in chronic rhinosinusitis with nasal polyps6
Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS)6
Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Me6
Autoimmune disorders associated with common variable immunodeficiency: prediction, diagnosis, and treatment6
Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma6
The oft-overlooked cardiovascular complications of inflammatory bowel disease6
Translational characterization of immune pathways in inflammatory bowel disease: insights for targeted treatments6
Antiphospholipid antibodies and osteonecrosis in systemic lupus erythematosus: a meta-analysis6
Innovative cell therapies for systemic sclerosis: available evidence and new perspectives6
The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders6
Plasma exchange as an adjunctive therapy in anti-neutrophil cytoplasm antibody-associated vasculitis6
Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update6
Serum exosomal long noncoding RNA nuclear-enriched abundant transcript 1 predicts 90-day mortality in acute-on-chronic hepatitis B liver failure5
A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis5
How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?5
Heterogeneity in myasthenia gravis: considerations for disease management5
How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies5
Rheumatic masqueraders: mimics of primary vasculitis - a case-based review5
Pathways of atopic disease and neurodevelopmental impairment: assessing the evidence for infant antibiotics5
Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus5
SLE criteria are by necessity still based on clinical (and immunological) criteria items5
An exercise immune fitness test to unravel mechanisms of Post-Acute Sequelae of COVID-195
Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights5
Considerations for managing elderly patients with atopic dermatitis5
Current treatment options and long-term outcomes in patients with eosinophilic esophagitis5
Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus5
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic5
Conventional and new immunotherapies for immune system dysregulation in postpartum mood disorders: comparisons to immune system dysregulations in bipolar disorder, major depression, and postpartum aut5
A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis5
Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons5
Pro-inflammatory cytokines in spondyloarthritis: a case-control study5
Comparing available treatments for pollen-induced allergic rhinitis in children5
Gut immune homeostasis: the immunomodulatory role of Bacillus clausii, from basic to clinical evidence5
Establishing diagnostic strategies for cannabis allergy5
How do nuclear factor kappa B (NF-κB)1 and NF-κB2 defects lead to the incidence of clinical and immunological manifestations of inborn errors of immunity?5
Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis5
Recent insights into the pathogenesis of autoimmune hypophysitis5
Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus5
Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective5
The management of women of childbearing age with rheumatoid arthritis: an expert report5
Biomarkers for systemic lupus erythematosus – a focus on organ damage5
Tailored biological treatment for patients with moderate-to-severe psoriasis4
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis4
Management and treatment optimization of patients with mild to moderate ulcerative colitis4
Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults4
Comparing treatment options for large vessel vasculitis4
Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults4
An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?4
Impact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenocarcinoma: a retrospective cohort study4
Mucosal and systemic immune responses to Vibrio cholerae infection and oral cholera vaccines (OCVs) in humans: a systematic review4
Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives4
Enthesitis-related arthritis and spondylarthritis: the same disease or disparate entities?4
The emerging role of IL-23 in asthma and its clinical implications4
Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis4
Epithelial cell dysfunction in chronic rhinosinusitis: the epithelial–mesenchymal transition4
A comparative review of immunoassays for COVID-19 detection4
5 reasons to encourage anti-SARS-CoV-2 vaccination in patients with rheumatic diseases4
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives4
Neurological adverse effects of chimeric antigen receptor T-cell therapy4
Biologics for chronic spontaneous urticaria: toward a personalized treatment4
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection4
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis4
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps4
Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits4
Topical and systemic JAK inhibitors in hand eczema – a narrative review4
The functional role and the clinical application of periostin in chronic rhinosinusitis4
The role of PCSK9 in inflammation, immunity, and autoimmune diseases4
French Guiana and AGS: a path to uncovering hidden clues4
Probiotics in asthma management: fiction or truth?4
Transcriptional regulation of B cell class-switch recombination: the role in development of noninfectious complications4
Diagnosis and clinical management of Wiskott–Aldrich syndrome: current and emerging techniques4
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis4
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy4
Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitors4
The role of interleukins in pathogenesis and prognosis of atrial fibrillation4
Classification and management strategies for paediatric chronic nonbacterial osteomyelitis and chronic recurrent multifocal osteomyelitis4
Linking stress and inflammation – is there a missing piece in the puzzle?4
Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation4
Hematological involvement in sarcoidosis: from cytopenias to lymphoma4
Durability and long-term outcomes of biologic therapies in psoriasis4
Response to letter to the editor: the clinical utility of diagnostic T cell assays for COVID-194
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?4
Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function4
Ten clinical conundrums in the management of eosinophilic granulomatosis with polyangiitis4
Interleukin polymorphisms and protein levels associated with lung cancer susceptibility and phenotypes4
Immune mechanisms, the role of complement, and related therapies in autoimmune neuropathies3
Changes in health-related quality of life in common variable immunodeficiency: an eight-year journey, including the COVID-19 pandemic3
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials3
In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges3
Examining the associations between COVID-19 infection and pediatric type 1 diabetes3
Avacopan for the treatment of ANCA-associated vasculitis: an update3
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events3
Phosphatidylinositol 3-kinase signaling and immune regulation: insights into disease pathogenesis and clinical implications3
Correction3
Neuro-ophthalmic challenges and multi-morbidity in vasculitis among the older adults3
New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis3
Correction3
Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis3
Proteomics approach for biomarker discovery in Kawasaki disease3
A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults3
Patch testing while immunosuppressed: potential risks and benefits3
0.12846302986145